These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12870684)

  • 1. Clinical and programmatic considerations in the treatment of MDR-TB in children: a series of 16 patients from Lima, Peru.
    Mukherjee JS; Joseph JK; Rich ML; Shin SS; Furin JJ; Seung KJ; Sloutsky A; Socci AR; Vanderwarker C; Vasquez L; Palacios E; Guerra D; Viru FA; Farmer P; Del Castillo HE
    Int J Tuberc Lung Dis; 2003 Jul; 7(7):637-44. PubMed ID: 12870684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Multidrug resistant tuberculosis in Romania in the last years (2004-2007)--an extremely important social phenomenon].
    Marica C; Didilescu C; Chiotan D; Galie N; Tănăsescu M; Popescu-Hagen M; Popa M
    Pneumologia; 2008; 57(4):195-200. PubMed ID: 19186681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru.
    Chavez Pachas AM; Blank R; Smith Fawzi MC; Bayona J; Becerra MC; Mitnick CD
    Int J Tuberc Lung Dis; 2004 Jan; 8(1):52-8. PubMed ID: 14974746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis.
    Laserson KF; Thorpe LE; Leimane V; Weyer K; Mitnick CD; Riekstina V; Zarovska E; Rich ML; Fraser HS; Alarcón E; Cegielski JP; Grzemska M; Gupta R; Espinal M
    Int J Tuberc Lung Dis; 2005 Jun; 9(6):640-5. PubMed ID: 15971391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impact of anti-tuberculosis drug resistance on treatment outcome of pulmonary tuberculosis patients receiving directly observed treatment strategy in Henan Province, China].
    Wang GJ; Xu JY; Wang GB; Zhen XA; Gao SY; Du CM
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Aug; 29(8):527-30. PubMed ID: 17074265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance.
    Cox H; Kebede Y; Allamuratova S; Ismailov G; Davletmuratova Z; Byrnes G; Stone C; Niemann S; Rüsch-Gerdes S; Blok L; Doshetov D
    PLoS Med; 2006 Oct; 3(10):e384. PubMed ID: 17020405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
    Kam KM; Yip CW
    Int J Tuberc Lung Dis; 2004 Jun; 8(6):760-6. PubMed ID: 15182147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of multi-drug resistant tuberculosis: practitioner's view point.
    Prasad R
    Indian J Tuberc; 2007 Jan; 54(1):3-11. PubMed ID: 17455417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
    Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus TB program in Latvia.
    Riekstina V; Leimane V; Holtz TH; Leimans J; Wells CD
    Int J Tuberc Lung Dis; 2007 May; 11(5):585-7. PubMed ID: 17439686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of individualised treatment for multidrug-resistant tuberculosis before DOTS-plus.
    Ollé-Goig JE; Sandy R
    Int J Tuberc Lung Dis; 2005 Jul; 9(7):765-70. PubMed ID: 16013772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistance profiles of Mycobacterium tuberculosis isolates: five years' experience and insight into treatment strategies for MDR-TB in Lima, Peru.
    Timperi R; Han LL; Sloutsky A; Becerra MC; Nardell EA; Salazar JJ; Smith-Fawzi MC
    Int J Tuberc Lung Dis; 2005 Feb; 9(2):175-80. PubMed ID: 15732737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia.
    Shin SS; Pasechnikov AD; Gelmanova IY; Peremitin GG; Strelis AK; Mishustin S; Barnashov A; Karpeichik Y; Andreev YG; Golubchikova VT; Tonkel TP; Yanova GV; Nikiforov M; Yedilbayev A; Mukherjee JS; Furin JJ; Barry DJ; Farmer PE; Rich ML; Keshavjee S
    Int J Tuberc Lung Dis; 2006 Apr; 10(4):402-8. PubMed ID: 16602404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance.
    Cox HS; Niemann S; Ismailov G; Doshetov D; Orozco JD; Blok L; Rüsch-Gerdes S; Kebede Y
    Clin Infect Dis; 2007 Jun; 44(11):1421-7. PubMed ID: 17479936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contact investigations as a means of detection and timely treatment of persons with infectious multidrug-resistant tuberculosis.
    Bayona J; Chavez-Pachas AM; Palacios E; Llaro K; Sapag R; Becerra MC
    Int J Tuberc Lung Dis; 2003 Dec; 7(12 Suppl 3):S501-9. PubMed ID: 14677844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea.
    Park SK; Lee WC; Lee DH; Mitnick CD; Han L; Seung KJ
    Int J Tuberc Lung Dis; 2004 Mar; 8(3):361-8. PubMed ID: 15139476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberculosis drug resistance and treatment outcomes under DOTS settings in large cities in the Philippines.
    Ohkado A; Aguiman L; Adlawan S; Baring E; Quirante O; Suchi M; Endo S; Fujiki A; Mori T
    Int J Tuberc Lung Dis; 2006 Mar; 10(3):283-9. PubMed ID: 16562708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.